Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current treatment options for myeloma.

Evangelos Terpos1, Amin Rahemtulla, Meletios-Athanassios Dimopoulos

  • 1Department of Haematology, 1251 General Air Force Hospital, 5 Marathonomahon Street, Drossia Attikis, 14572, Greece. e.terpos@imperial.ac.uk

Expert Opinion on Pharmacotherapy
|June 17, 2005
PubMed
Summary

Multiple myeloma remains largely incurable, with frequent relapses after conventional treatments like autologous stem cell transplantation (ASCT). This review explores current and novel therapies, including targeted agents and transplantation options, for managing this plasma cell malignancy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study.

Leukemia·2021
Same author

Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance.

Clinical lymphoma, myeloma & leukemia·2021
Same author

Integrin expression in correlation to clinicopathological features and prognosis of prostate cancer: A systematic review and meta-analysis.

Urologic oncology·2021
Same author

Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.

Blood advances·2021
Same author

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

HemaSphere·2021
Same author

Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.

The Lancet. Oncology·2021

Area of Science:

  • Hematology
  • Oncology
  • Clinical Therapeutics

Background:

  • Multiple myeloma is an incurable plasma cell malignancy with high relapse rates.
  • Current treatments like conventional therapy and autologous stem cell transplantation (ASCT) offer limited long-term cures.
  • Novel therapeutic strategies are emerging for relapsed/refractory disease.

Purpose of the Study:

  • To review current treatment options for multiple myeloma.
  • To address unanswered questions regarding ASCT safety in elderly patients and the role of allogeneic transplantation.
  • To evaluate the impact of novel agents (thalidomide, bortezomib) in newly diagnosed and post-ASCT patients.

Main Methods:

  • Comprehensive review of existing data on multiple myeloma management.

Related Experiment Videos

  • Analysis of treatment outcomes for conventional therapy, ASCT, and allogeneic transplantation.
  • Evaluation of novel drug efficacy in different treatment settings.

    • Main Results:

    • ASCT is the current standard for eligible patients, but relapse remains common.
    • Allogeneic transplantation offers a potential cure for a minority of patients.
    • Novel agents show promise in relapsed/refractory disease and potentially in newly diagnosed patients or as maintenance therapy.

    Conclusions:

    • Multiple myeloma management requires ongoing research into optimal treatment strategies.
    • The role of novel agents and alternative transplantation methods needs further clarification.
    • This review provides an algorithm to guide the management of multiple myeloma patients.